Core Insights - Royal Philips has announced the CE-marking of its SmartCT image reconstruction solution, enhancing decision-making in stroke and neurovascular treatment [1][3] - SmartCT is designed for the Philips Azurion neuro biplane system, providing real-time 3D imaging directly in the Angio suite, which accelerates treatment and improves clarity [2][9] - The technology is already in use at leading stroke centers globally, streamlining workflows and supporting timely interventions, particularly in mechanical thrombectomy procedures [3][4] Product Features - SmartCT 3.0 delivers cone-beam CT imaging in as little as 8 seconds, optimizing image quality for cerebral soft tissue and aiding in the visualization of vessel occlusions [9] - The system includes motion-compensated imaging for restless patients and features like SmartCT Dual Viewer for real-time image fusion and enhanced procedural planning [9] - Philips will showcase SmartCT 3.0 at LINNC Paris 2025, highlighting its capabilities for neuro-endovascular treatments [6] Company Overview - Royal Philips is a leading health technology company focused on improving health and well-being through innovation, with 2024 sales of EUR 18 billion and operations in over 100 countries [10][11] - The company specializes in diagnostic imaging, ultrasound, image-guided therapy, and personal health solutions, employing approximately 67,200 people [11]

Core Insights - Royal Philips has launched the RADIQAL trial, a multicenter, randomized study aimed at evaluating the effectiveness of its new ultra-low X-ray dose technology in reducing radiation exposure during coronary procedures without compromising image quality or procedural performance [1][3][10] Company Overview - Royal Philips is a leading health technology company focused on improving health and well-being through innovation, generating sales of EUR 18 billion in 2024 and employing approximately 67,200 people globally [6] Trial Details - The RADIQAL trial will enroll 824 patients with coronary artery disease across six hospitals in Spain, Czech Republic, Denmark, and the US, with the primary objective of demonstrating reduced radiation doses without affecting the performance of coronary procedures [1][10] - The new technology is designed to reduce X-ray exposure by 50% compared to the lowest settings of the existing ClarityIQ technology integrated into the Azurion image-guided therapy system [3][4] Clinical Importance - Reducing radiation exposure while maintaining or improving image quality is a critical goal in interventional cardiology, especially for patients with high BMI or complex conditions requiring multiple interventions [4]